Novartis Settles Criminal, Qui Tam Cases For $422.5M

Law360, New York (September 30, 2010, 2:29 PM EDT) -- Novartis Pharmaceuticals Corp. has agreed to shell out $237.5 million to settle civil allegations that it promoted the epilepsy drug Trileptal for off-label uses and paid kickbacks to get doctors to prescribe Trileptal and other drugs, an agreement that comes on top of a $185 million deal to resolve a criminal probe into Trileptal's marketing.

The deal covers four qui tam suits alleging the company unlawfully marketed Trileptal, Diovan, Zelnorm, Sandostatin, Exforge and Tekturna and caused false claims to be submitted to federal health care programs,...
To view the full article, register now.